Imacent 100: Each tablet contains Imatinib Mesylate INN equivalent to Imatinib 100 mg.
Imacent 400: Each tablet contains Imatinib Mesylate INN equivalent to Imatinib 400 mg.
Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase; the
constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML.
Imatinib inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh
leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits
colony formation in assays using ex vivo peripheral blood and bone marrow samples from CML
In vivo, Imatinib inhibits tumor growth of BCR-ABL transfected murine myeloid cells as well as
BCR-ABL positive leukemia lines derived from CML patients in blast crisis.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF)
and stem cell factor (SCF), c-kit, and inhibits PDGF and SCF mediated cellular events. In vitro,
Imatinib inhibits proliferation and induces apoptosis in gastrointestinal stromal tumor (GISTs) cells,
which express an activating c-kit mutation.
Imatinib is indicated for the treatment of:
Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid
leukemia (Ph+ CML) in chronic phase. Patients with Philadelphia chromosome positive chronic
myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP)
after failure of interferon-alpha therapy
Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic
leukemia (Ph+ ALL). Pediatric patients with newly diagnosed Philadelphia chromosome positive
acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy
Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR
(platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved
Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as
determined with an FDA-approved test or with c-Kit mutational status unknown
Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL)
who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2
allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase
negative or unknown
Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans
Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal
Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST
The recommended dose for Imatinib are-
- Adults with Ph+ CML CP: 400 mg/day
- Adults with Ph+ CML AP or BC: 600 mg/day
- Pediatrics with Ph+ CML CP: 340 mg/m2/day
- Adults with Ph+ ALL: 600 mg/day
- Pediatrics with Ph+ ALL: 340 mg/m2/day
- Adults with MDS/MPD: 400 mg/day
- Adults with ASM: 100 mg/day or 400 mg/day
- Adults with HES/CEL: 100 mg/day or 400 mg/day
- Adults with DFSP: 800 mg/day
- Adults with metastatic and/or unresectable GIST: 400 mg/day
- Adjuvant tratment of adults with GIST: 400 mg/day
- Patients with mild to moderate hepatic impairment: 400 mg/day
- Patients with severe hepatic impairment: 300 mg/day
The most frequently reported adverse reactions (greater than or equal to 30%) were edema, nausea,
vomiting, muscle cramps, musculoskeletal pain, diarrhea, rash, fatigue and abdominal pain.
- Edema and severe fluid retention have occurred. Weigh patients regularly and manage unexpected
rapid weight gain by drug interruption and diuretics.
- Cytopenias, particularly anemia, neutropenia, and thrombocytopenia, have occurred. Manage with
dose reduction, dose interruption, or discontinuation of treatment. Perform complete blood counts
weekly for the first month, biweekly for the second month, and periodically thereafter.
- Severe congestive heart failure and left ventricular dysfunction have been reported, particularly in
patients with comorbidities and risk factors. Monitor and treat patients with cardiac disease or risk
factors for cardiac failure.
- Severe hepatotoxicity including fatalities may occur. - -- - Assess liver function before initiation of
treatment and monthly thereafter or as clinically indicated. -- Monitor liver function when combined
with chemotherapy known to be associated with liver dysfunction.
- Grade 3/4 hemorrhage has been reported in clinical studies in patients with newly diagnosed CML
and with GIST. GI tumor sites may be the source of GI bleeds in GIST.
- Gastrointestinal perforations, some fatal, have been reported.
- Cardiogenic shock/left ventricular dysfunction has been associated with the initiation of Imatinib in
patients with conditions associated with high eosinophil levels (e.g., HES, MDS/MPD and ASM).
- Bullous dermatologic reactions (e.g., erythema multiforme and Stevens-Johnson syndrome) have
been reported with the use of Imatinib.
- Hypothyroidism has been reported in thyroidectomy patients undergoing levothyroxine replacement.
- Closely monitor TSH levels in such patients.
- Fetal harm can occur when administered to a pregnant woman. Apprise women of the potential
harm to the fetus, and to avoid pregnancy when taking Imatinib.
- Growth retardation occurring in children and pre-adolescents receiving Imatinib has been reported.
- Close monitoring of growth in children under Imatinib treatment is recommended.
- Tumor lysis syndrome. Close monitoring is recommended.
- Reports of motor vehicle accidents have been received in patients receiving Imatinib. Caution
patients about driving a car or operating machinery.
- Renal toxicity. A decline in renal function may occur in patients receiving Imatinib. Evaluate renal
function at baseline and during therapy, with attention to risk factors for renal dysfunction.
Imatinib can cause fetal harm when administered to a pregnant woman based on human and animal
data. There are no clinical studies regarding use of Imatinib in pregnant women. There have been
postmarket reports of spontaneous abortions and congenital anomalies from women who have been
exposed to Imatinib during pregnancy. Reproductive studies in rats have demonstrated that Imatinib
mesylate induced teratogenicity and increased incidence of congenital abnormalities following prenatal
exposure to Imatinib mesylate at doses equal to the highest recommended human dose of 800
mg/day based on body surface area. Women should be advised to avoid pregnancy when taking
Imatinib. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this
drug, the patient should be apprised of the potential hazard to the fetus.
The background risk of major birth defects and miscarriage for the indicated population is not known;
however, in the U.S. general population, the estimated background risk of major birth defects of
clinically recognized pregnancies is 2-4% and of miscarriage is 15%-20%.
Imatinib and its active metabolite are excreted into human milk. Because of the potential for serious
adverse reactions in breastfed infants from Imatinib, advise a lactating woman not to breastfeed during
treatment and for 1 month after the last dose.
The safety and effectiveness of Imatinib have been demonstrated in pediatric patients with newly
diagnosed Ph+ chronic phase CML and Ph+ ALL. There are no data in children under 1 year of age.
In the CML clinical studies, approximately 20% of patients were older than 65 years. In the study of
patients with newly diagnosed CML, 6% of patients were older than 65 years. The frequency of edema
was higher in patients older than 65 years as compared to younger patients; no other difference in the
safety profile was observed. The efficacy of Imatinib was similar in older and younger patients.
The effect of hepatic impairment on the pharmacokinetics of both Imatinib and its major metabolite,
CGP74588, was assessed in 84 patients with cancer with varying degrees of hepatic impairment at
Imatinib doses ranging from 100 mg to 800 mg.
Mild and moderate hepatic impairment do not influence exposure to Imatinib and CGP74588. In
patients with severe hepatic impairment, the Imatinib Cmax and area under curve (AUC) increased by
63% and 45% and the CGP74588 Cmax and AUC increased by 56% and 55%, relative to patients
with normal hepatic function. Reduce the dose by 25% for patients with severe hepatic impairment.
The effect of renal impairment on the pharmacokinetics of Imatinib was assessed in 59 patients with
cancer and varying degrees of renal impairment at single and steady state Imatinib doses ranging
from 100 to 800 mg/day. The mean exposure to Imatinib (dose normalized AUC) in patients with mild
and moderate renal impairment increased 1.5- to 2-fold compared to patients with normal renal
function. There are not sufficient data in patients with severe renal impairment. Dose reductions are
necessary for patients with moderate and severe renal impairment.
CYP3A4 inducers may decrease Imatinib Cmax and area under curve (AUC)
CYP3A4 inhibitors may increase Imatinib Cmax and AUC
Imatinib is an inhibitor of CYP3A4 and CYP2D6 which may increase the Cmax and AUC of other
Patients who require anticoagulation should receive low-molecular weight or standard heparin and
Do not store above 30°C.
Imacent 100: Each box contains 3 blister of 10 tablets.
Imacent 400: Each box contains 3 blister of 10 tablets.